avalw
⚲
WHO Slams the Door on GLP-1s for Under-10s HEALTH · US

WHO Slams the Door on GLP-1s for Under-10s

Ursula Hayes Ursula Hayes ursulahayes.avalw.com · 37 reads Respect0 Save Share Read only
READS14live count PUBLISHED9 Oct2026 READING TIME3 min628 words LANGUAGEEnglish
AI CITATIONS? Gathering data

The World Health Organization has issued a strong recommendation against obesity drugs for children under ten, prioritizing lifestyle changes over medical intervention.

ALSO ON THE CREATOR SITERead this on ursulahayes.avalw.comOpen

Dr. Luz De Rigil did not mince words when the World Health Organization released its latest global guidelines this week. For children under the age of ten, the organization does not recommend obesity medicines, bariatric surgery, or weight management devices. This is a strong recommendation, not a gentle suggestion. It is a clear line drawn in the sand for a generation of young patients who have been increasingly funneled into pharmaceutical solutions for weight management.

The context is alarming. Seventy million children between the ages of five and nine are currently classified as obese. The prevalence in this demographic has skyrocketed from 2 percent in 1990 to 8 percent today. As of 2024, about 35 million children under five are expected to be overweight. In the face of these staggering numbers, the WHO is urging a return to foundational health practices rather than immediate medicalization.

The Pushback Against Medicalization

Some medications, such as Mounjaro and Wegovy, have been tested in children as young as six. The pharmaceutical industry has aggressively pushed these treatments into the pediatric market, promising rapid results and improved metabolic health. However, the WHO asserts that these treatments should not be used in younger patients. The organization maintains a clear position against their use in the under-ten demographic, emphasizing that the long-term effects of chronic GLP-1 use in developing bodies are not fully understood.

Laurence Grummer-Strawn, head of Nutrition and Food Safety Actions at WHO, expressed deep caution regarding this trend. He questioned the logic of using these drugs as a temporary fix, noting that we do not really have evidence that you can use this as a temporary treatment and then turn to something dietary later on in life. This is a critical gap in the current medical narrative. We are jumping in without clear evidence of how to safely exit these treatments once the child is older.

The WHO emphasizes the importance of healthy eating as a primary intervention.
The WHO emphasizes the importance of healthy eating as a primary intervention.

Lifestyle as the First Line

The WHO’s recommendations highlight a focus on promoting healthy eating and exercise rather than resorting to medical or surgical interventions. This is a holistic approach that views the child as a whole person, not just a set of metabolic markers to be corrected. The organization suggests that certain digital tools, such as activity trackers and online games that promote movement, could be beneficial. While the evidence supporting these strategies remains limited, they represent a less invasive and more sustainable path forward.

Interventions might be suitable for older children and adolescents, but only when lifestyle modifications fail and if the young individual is ready, both mentally and physically. This nuance is crucial. It acknowledges that adolescence is a time of significant physical and emotional change, and that medical intervention should be a last resort, not a first option. The goal is to safeguard the health and well-being of young people without subjecting them to unnecessary pharmaceutical risks.

Physical activity is central to the new guidelines for young children.
Physical activity is central to the new guidelines for young children.

The Long-Term Risk

Obesity can lead to various health complications, such as type 2 diabetes and other serious conditions. The temptation to reach for a pill is understandable, especially when the stakes are so high. However, the WHO’s stance is a warning against short-term thinking. Using drugs in very young children creates a dependency on medical management that may not be sustainable or safe over a lifetime. We are potentially trading one set of health risks for another, without fully understanding the long-term consequences.

This is a critical shift in managing childhood obesity. It aims to safeguard the health and well-being of young people by prioritizing their natural development and the power of behavioral change. The guidelines are a call to action for parents, educators, and healthcare providers to rethink how they approach weight management in children. It is a reminder that the most powerful tools for health are often the simplest, and that medical intervention should always be preceded by a robust attempt at lifestyle modification.

Digital tools are suggested as a supportive, non-invasive measure.
Digital tools are suggested as a supportive, non-invasive measure.

Frequently asked questions

What is the WHO recommendation for treating obesity in children under ten?

The World Health Organization strongly advises against using obesity medicines, bariatric surgery, or weight management devices for children under the age of ten. This position prioritizes foundational health practices over immediate medicalization for this specific demographic.

Why does the WHO oppose the use of GLP-1 drugs in young children?

The organization cites a lack of evidence regarding the long-term effects of chronic GLP-1 use in developing bodies. It also notes that there is no clear data supporting the safe transition from these drugs to dietary management later in life.

How many children aged five to nine are currently classified as obese?

Seventy million children in this age group are currently classified as obese. This represents a significant increase from a prevalence rate of 2 percent in 1990 to 8 percent today.

Which specific medications have been tested in children as young as six?

Mounjaro and Wegovy are the specific medications mentioned that have undergone testing in children as young as six years old. The pharmaceutical industry has promoted these treatments for the pediatric market despite the WHO's caution.

What alternative approach does the WHO suggest for managing childhood weight?

The WHO recommends focusing on healthy eating and exercise as the primary intervention. It also suggests that digital tools like activity trackers and movement-promoting games may be beneficial, although evidence for these strategies remains limited.

When might medical interventions be considered for older children and adolescents?

Interventions are suitable for older youth only when lifestyle modifications have failed and the individual is mentally and physically ready. The WHO emphasizes that medical treatment should remain a last resort rather than a first option.

0 responses
No responses yet. Be the first to add one.
Ursula Hayes
Follow this desk
Ursula Hayes
Create a free account to follow Ursula Hayes. New stories land in your feed, and you can save any of them to your own reading lists.
Your library & lists →
Ursula Hayes
WRITTEN BY THE AUTHOR
Ursula Hayes 2026-10-09 · 3 min read · 14 reads
View profile →
VERIFY THIS STORY
ASK AI
Ursula Hayes Keep subscribing to Ursula HayesHer next filing reaches you the moment it publishes, on her own subdomain.
Up next
More
Statistics Search Become a creator Alliances About Terms Privacy